Literature DB >> 33670062

Expression and Prognostic Characteristics of m6A RNA Methylation Regulators in Colon Cancer.

Liting Huang1, Jie Zhu2, Weikaixin Kong2, Peifeng Li1, Sujie Zhu1.   

Abstract

Colon cancer is a common and leading cause of death and malignancy worldwide. N6-methylation of adenosine (m6A) is the most common reversible mRNA modification in eukaryotes, and it plays a crucial role in various biological functions in vivo. Dysregulated expression and genetic changes of m6A regulators have been correlated with tumorigenesis, cancer cell proliferation, tumor microenvironment, and prognosis in cancers. This study used RNA-seq and colon cancer clinical data to explore the relationship between N6-methylation and colon cancer. Based on the seven m6A regulators related to prognosis, three molecular subgroups of colon cancer were identified. Surprisingly, we found that each subgroup had unique survival characteristics. We then identified three subtypes of tumors based on 299 m6A phenotype-related genes, and one subtype was characterized as an immunosuppressive tumor and patients in this subtype may be more suitable for immunotherapy than other subtypes. Finally, using m6A-related genes and clinical information from The Cancer Genome Atlas cohort, we constructed a prognosis model, and this model could be used to predict the prognosis of patients in clinics.

Entities:  

Keywords:  colon cancer; immunity; m6A regulators; prognosis

Mesh:

Substances:

Year:  2021        PMID: 33670062      PMCID: PMC7926939          DOI: 10.3390/ijms22042134

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  42 in total

1.  Genome-Wide Location Analyses of N6-Methyladenosine Modifications (m6A-Seq).

Authors:  Benoit Molinie; Cosmas C Giallourakis
Journal:  Methods Mol Biol       Date:  2017

2.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C Chan; Joseph M Connors; Elias Campo; Randy D Gascoyne; Thomas M Grogan; H Konrad Muller-Hermelink; Erlend B Smeland; Michael Chiorazzi; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Sarah Henrickson; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Emilio Montserrat; Francesc Bosch; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Richard I Fisher; Thomas P Miller; Michael LeBlanc; German Ott; Stein Kvaloy; Harald Holte; Jan Delabie; Louis M Staudt
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

3.  Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells.

Authors:  R Desrosiers; K Friderici; F Rottman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

4.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking.

Authors:  Matthew D Wilkerson; D Neil Hayes
Journal:  Bioinformatics       Date:  2010-04-28       Impact factor: 6.937

5.  MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer.

Authors:  Guohong Hu; Robert A Chong; Qifeng Yang; Yong Wei; Mario A Blanco; Feng Li; Michael Reiss; Jessie L-S Au; Bruce G Haffty; Yibin Kang
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

6.  Integrating systemic module inference with attract method excavates attractor modules for cyclophosphamide contributing to prostate cancer.

Authors:  Guodong Sun; Wenjing Zhang; Jing Wang
Journal:  J Cancer Res Ther       Date:  2019-03       Impact factor: 1.805

7.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer.

Authors:  Bo Zhang; Qiong Wu; Ben Li; Defeng Wang; Lei Wang; You Lang Zhou
Journal:  Mol Cancer       Date:  2020-03-12       Impact factor: 27.401

9.  Gene Alterations of N6-Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study.

Authors:  Qian Zhang; Yuping Cai; Vadim Kurbatov; Sajid A Khan; Lingeng Lu; Yawei Zhang; Caroline H Johnson
Journal:  Biomed Res Int       Date:  2020-12-19       Impact factor: 3.411

10.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.

Authors:  Yang Li; Lihua Zou; Qiyuan Li; Benjamin Haibe-Kains; Ruiyang Tian; Yan Li; Christine Desmedt; Christos Sotiriou; Zoltan Szallasi; J Dirk Iglehart; Andrea L Richardson; Zhigang Charles Wang
Journal:  Nat Med       Date:  2010-01-24       Impact factor: 53.440

View more
  2 in total

1.  Molecular Characterization and Clinical Relevance of N6-Methyladenosine Regulators in Metastatic Prostate Cancer.

Authors:  Qiwei Liu; Zhen Li; Lizhao He; Ke Li; Chen Hu; Jialiang Chen; Fangjian Zhou; Jun Wang; Yonghong Li; Hengjun Xiao
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

2.  Alteration of m6A epitranscriptomic tagging of ribonucleic acids after spinal cord injury in mice.

Authors:  Shuangfei Ni; Zixiang Luo; Yonggang Fan; Weixin Zhang; Wei Peng; Huafeng Zhang
Journal:  Front Neurosci       Date:  2022-08-25       Impact factor: 5.152

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.